Friday, July 21, 2017
Project co-funded by the European Commission in the framework of the 2nd Health Programme
Enter Title Minimize

 

5. TRACEABILITY AND VIGILANCE

  • 5.1.Serious adverse reactions/events
  • 5.2. Notification of serious adverse reactions (Recipients)
  • 5.3. Notification of serious adverse reactions (Living donors)
  • 5.4. Notification of serious adverse events

 

Print  
A3f Engine ::Terms Of Use::Privacy Statement